HBK Capital Management

Resilient Network Systems specializes in developing advanced Internet servers and contextual access management software that enhance data security and application control. Their innovative technology allows users to securely share sensitive information while maintaining customized control over access and usage. The company’s software features traditional security measures such as single sign-on and multi-factor authentication, combined with a flexible policy workflow engine. This enables organizations to implement tailored access rules for files, applications, and documents, effectively safeguarding their content. By brokering and enforcing security policies between all parties before transactions occur, Resilient Network Systems addresses concerns about unauthorized access to valuable or private data, thereby facilitating secure interactions across various ecosystems.

EUSA Pharma, founded in March 2006 and headquartered in the UK, is a profitable specialty pharmaceutical company that operates globally with a focus on oncology and other critical diseases. The company markets a portfolio of five approved specialty hospital products, including Caphosol®, Xenazine®, Collatamp®, Custodiol®, and Fomepizole®, along with several named-patient products. EUSA Pharma is dedicated to addressing rare diseases and conditions such as oral mucositis, a common side effect of cancer treatments. The company has submitted a Marketing Authorization Application for FOTIVDA (tivozanib HCL) as a first-line therapy for renal cell carcinoma. With plans to expand its portfolio through acquisitions and in-licensing, EUSA Pharma's operations extend across Europe and the USA, supported by a network of commercial partners in Europe, the Middle East, Asia, and Latin America, making its products available in approximately 40 countries worldwide. The company is led by an experienced management team with a strong track record in the specialty pharmaceutical sector.